Cediranib
Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
Fox Chase Cancer CenterSmall moleculePhase 1Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cetuximab Fox Chase Cancer Center | Phase 1/2 | B |
Irinotecan National Cancer Institute (NCI) | Phase 1/2 | B |
(+)-VINCRISTINE National Cancer Institute (NCI) | Phase 1/2 | CCC |
FLUDEOXYGLUCOSE Sanjiv Sam Gambhir | Phase 1/2 | CCC |
(18F)FPPRGD2 Sanjiv Sam Gambhir | Phase 1/2 | CCC |
View all 9 →
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →